METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Drug attack on Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing whether adding a new drug called SX-682 to an existing prostate cancer drug (apalutamide) is safe and can help control advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It will involve about 78 men whose cancer h…
Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough prostate cancer: trial tests promising drug combo
Disease control Recruiting nowThis study is testing whether adding an experimental drug called mevrometostat to a standard prostate cancer medicine (enzalutamide) works better than current standard treatments for men with advanced prostate cancer that has spread and is no longer responding to prior therapy. I…
Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
First-in-Human trial tests engineered immune cells against tough prostate cancer
Disease control Recruiting nowThis early-stage study is testing a new type of personalized immune cell therapy called TmPSMA-02 CAR T cells in men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The main goals are to find a safe dose and see if the body can…
Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New 'Alpha' cancer drug enters human testing for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of a new experimental drug called AB001 for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The drug is a type of targeted radiation therapy designed to…
Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: ARTBIO Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Custom radiation doses tested in fight against spreading prostate cancer
Disease control Recruiting nowThis study is testing whether personalized radiation doses can be safely increased for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. Researchers will compare customized treatment plans based on kidney radiation measurements against s…
Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Jean-Mathieu Beauregard • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC